Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease

Abstract

A normalised FC level has the potential to be used as a surrogate marker for successful treatment outcome in IBD patients. However, patients with persistent elevation of FC levels need further evaluation. FC and MPO provide superior discrimination than EPX in IBD treatment outcome.